胰腺癌治疗困难，KRASG12D突变常见。研究人员合成金纳米粒子 - 白藜芦醇复合物（GRs）研究其抗癌活性。结果显示 GRs 能抑制 AsPC-1 细胞活力、诱导凋亡。这为胰腺癌治疗提供新方向。

自1979年被发现以来，p53蛋白已成为了研究最为广泛和深入的肿瘤抑制因子之一。作为转录因子，p53调控众多下游信号通路，诱导细胞周期停滞、细胞凋亡和衰老是其最“经典”的功能，也被认为是其清除受损细胞、防止癌细胞发生的主要手段。学术经纬相关阅读：人类 ...

Wound closure was imaged via microscopy. For each image, the gap width was analyzed via ImageJ. HUVECs (1 × 10 4) in CM were seeded onto Matrigel (BD Biosciences)-coated μ-Slide angiogenesis plates ...

Impact Therapeutics Inc. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of neurologic cancer.

0.14-1.07). The researchers compared the combination of a PARP inhibitor and an anti-angiogenic agent to chemotherapy using data from 2 trials of patients with recurrent ovarian cancer.

The effects of caspases on cellular substrates bring about the biochemical and morphological features of apoptosis (Fig. 1). Caspase proenzymes ... polymerase (PARP) and degradation of ICAD ...

Satisfactory update 1.1 is on the way, and there’s lots to look forward to. Already beloved during its early access period, the open-world building game solidified its place alongside the likes ...

TALAPRO-2、MAGNITUDE及PROpel等III期临床试验推动PARP抑制剂联合ARP抑制剂的mCRPC适应症获批。 表1. 三种PARP抑制剂联合ARP抑制剂方案在欧盟、美国和中国大陆的mCRPC获批人群 研究发现，各种PARP抑制剂在“抑制PARP催化活性”和“捕获PARP与DNA损伤位点结合”这两方面的 ...

PARP 抑制剂（PARPi）用于治疗乳腺癌时疗效存在差异，为寻找更好的生物标志物，宾夕法尼亚大学研究人员评估 [18 F]FluorThanatrace（[18 F] FTT）PET 成像。结果显示，基线 [18 F] FTT - PET 摄取及治疗后的变化与无进展生存期相关，这为 PARPi 治疗提供新的生物标志物。 在 ...

DelveInsight’s, “Glioma Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Glioma pipeline landscape. It covers the Glioma pipeline drug ...

PARP 抑制剂被批准用于治疗携带 BRCA ... 并且化疗还有可能对患者的生活质量产生负面影响。 表 1. 国内外指南对于靶向药物和免疫药物的推荐线数 ...

Hypoxic kinetics in CCL39 and GSK3 cells at 1% O 2 are shown. HIF1α and β-actin levels were analyzed by Western blotting ... Antibodies recognizing β-actin (Sigma), PHD3 (Interchim and Novus ...